毒品濫用問題乃世界各國共通之施政難題，我國政府於1993年宣布向毒品宣戰，並在2005年8月引進美沙酮替代療法（Methadone Maintenance Treatment，MMT），於全國各縣市推動毒品減害計畫。但歷經十餘年之努力，毒品人口與整體毒品再犯率截至2010年底並未明顯降低，足見毒品防制政策有全面檢視問題癥結，重新調整執行策略之必要。本研究就此現象探討三項議題：1.毒品防制領域，IT有無著力之空間？ 2.以美沙酮替代療法為主之毒品防制策略在台灣地區推行是否發揮預期的效果？現行做法有無改善空間？ 3.出監毒癮者復歸社會後再犯率高，其最需要政府的幫助為何，方能有效降低再犯毒品罪之誘因？。三項議題互為關聯。 本研究探訪毒品防制第一線工作人員，並參考國內外毒品減害文獻，歸納目前毒品危害防制工作推動上的困境，探究IT可出力之空間，並提出“毒品成癮者資訊總歸戶”的概念。整合法務、警政、衛生醫療等毒品防制資訊，建立跨部會即時歸戶資料庫並建立部會間協同作業之標準作業程序（SOP），以提升毒品防制工作之效率。進而運用歸戶系統之客觀數據，評量毒品替代療法政策之推行成效，並實際訪問領域專家及調查毒品犯社會適應之困難與需求，以歸納具體、可行之解決方案。 研究發現資訊系統可改善毒品危害防制中心效率，但不能單獨讓毒品防制工作之網絡有效運轉，現行毒品防制組織、制度問題之發現與解決更是關鍵。本文並依客觀數據之分析及實地訪問、調查結果，提出多項制度變革之建議，以供政府權責機關參採。 / Background:Drug abuse problems have been a global concern issue. Taiwan’s government introduced Methadone Maintenance Treatment (MMT) in Aug. 2005, now it has become one of the major strategies in fighting drug abuse. Whereas, up to 2010 MMT strategy still not shows effectiveness in reduce drug population and recidivism. The aim of this study is to: Provide the value to the Drug Abuse Provention System in R.O.C.through IT approach,and to evaluate whether MMT is performed adequately in Taiwan.If not,what are the key factors? The study will provide objective evidence and suggestions to authorities for better decision making. Methods: This study used Prove of Concept (POC) and experiment approachs. Build software system and SOP to prove the concept of “National Drug Addicts Supporting and Monitoring System (NDASMS)” can enhance the efficiency of Information Intergration among government agencies of drug prevention effectively. The study also used the data of NDASMS to evaluate the efficacy of MMT implementation in Taiwan, and find the reasons why MMT dose not work as expected. Result: The IT approach have been proved that enhance the infromation integration effectively among agencies, but IT can,t make the Chain of National Drug Provention Mechanism improve alone.The adequacy of MMT implementation and its supporting measures in Taiwan need to be further examined.

No description available.

The thesis focuses on the subjectively perceived changes in the lives of persons in the methadone maintenance treatment program, on their experiencing of the changes and subjective judgment of the treatment. The topic is treated according to the Bio-Psycho-Socio-Spiritual Model of Addiction. The theoretical part deals with the quality of life and the subjectively perceived well-being and defines six dimensions of well-being on which the practical part of the thesis is based. It also elaborates on the Bio-Psycho-Socio-Spiritual Model of Addiction in the context of the methadone maintenance treatment. Moreover, it describes the factors in life change and the motivation to change. The last theoretical chapter focuses on the opioid substitution treatment as such and more specifically on the methadone maintenance treatment. The practical part presents the results of the research. The aim of the thesis is to analyse how the persons in the methadone maintenance treatment program in České Budějovice perceive life changes. A qualitative research was chosen for that purpose. The data were obtained through the technique of narrative interview. The research group consisted of four respondents who were on the methadone maintenance treatment program. The results show that the subjectively perceived changes in the lives of the persons in the methadone maintenance treatment program relate to five out of six dimensions of well-being. No changes were recorded in the dimension concerning the sense of life, in other words, even after a several month methadone maintenance treatment these persons perceive no goal of their lives. Important consequences for work with these persons can be drawn from that, especially for therapists in opioid substitution centres, who should develop spirituality aspects of persons.

Introduction: Malgré des taux d’efficacité comparable du traitement antiviral de l’hépatite C (VHC) entre utilisateurs de drogues par injection (UDIs) et non-UDIs, il y a encore d’importantes barrières à l’accessibilité au traitement pour cette population vulnérable. La méfiance des UDIs à l’égard des autorités médicales, ainsi que leur mode de vie souvent désorganisé ont un impact sur l’initiation du traitement. L’objectif de cette étude est d’examiner les liens entre l’initiation du traitement du VHC et l’utilisation des services de santé chez les UDIs actifs. Methode: 758 UDIs actifs et séropositifs aux anticorps anti-VHC ont été interrogés durant la période de novembre 2004 à mars 2011, dans la région de Montréal. Des questionnaires administrés par des intervieweurs ont fourni des informations sur les caractéristiques socio-économiques, ainsi que sur les variables relatives à l’usage de drogues et à l’utilisation des services de santé. Des échantillons sanguins ont été prélevés et testés pour les anticorps anti-VHC. Une régression logistique multivariée a permis de générer des associations entre les facteurs relatifs aux services de santé et l’initiation du traitement contre le VHC. Resultats: Parmi les 758 sujets, 55 (7,3%) avaient initié un traitement du VHC avant leur inclusion dans l’étude. Selon les analyses multivariées, les variables significativement associées à l’initiation du traitement sont les suivantes: avoir vu un médecin de famille dans les derniers 6 mois (Ratio de Cote ajusté (RCa): 1,96; Intervalle de Confiance à 95% (IC): 1,04-3,69); plus de 2 ans sous traitement de la dépendance à vie, sans usage actuel de méthadone (RCa: 2,25; IC: 1,12-4,51); plus de 2 ans sous traitement de la dépendance à vie, avec usage actuel de méthadone (RCa: 3,78; IC: 1,85-7,71); et avoir déjà séjourné en prison (RCa: 0,44; IC: 0,22-0,87). Conclusion: L’exposition à des services d’aide à la dépendance et aux services médicaux est associée à l’initiation du traitement du VHC. Ces résultats suggèrent que ces services jouent leur rôle de point d’entrée au traitement. Alternativement, les UDIs ayant initié un traitement du VHC, auraient possiblement adopté une attitude proactive quant à l'amélioration de leur santé globale. D’autre part, l’incarcération ressort comme un obstacle à la gestion de l’infection au VHC. / Introduction: In spite of comparable hepatitis C virus (HCV) treatment efficacy between injection drug users (IDUs) and non-IDUs, there are still important barriers impeding antiviral treatment access in this vulnerable population. Mistrust between IDUs and health care providers, along with IDU disorganised lifestyle, affect HCV treatment uptake. The objective of this study is to examine the association between HCV treatment initiation and the use of healthcare services among active IDUs. Methodology: 758 active IDUs, seropositive for anti-HCV antibody, were surveyed from November 2004 to March 2011 in Montreal. Interviewer-administered questionnaires elicited information on socio-demographic factors, drug use related behaviors and health care service utilization. Blood samples were collected and tested for HCV antibodies. Multivariate logistic regression analysis was conducted to identify the health service correlates of HCV treatment initiation. Results: Among the 758 subjects, 55 (7.3%) had initiated an HCV treatment prior to enrolment. In multivariate analysis, variables independently associated with treatment initiation included: having seen a general practitioner in the last 6 months (adjusted Odds Ratio (aOR): 1,96; 95% Confidence Interval (CI): 1,04-3,69); more than 2 years of lifetime addiction treatment exposure without current methadone use (aOR: 2,25; CI: 1,12-4,51); more than 2 years of lifetime addiction treatment exposure with current methadone use (aOR: 3,78; CI: 1,85-7,71); and having spent time in prison (aOR: 0,44; CI: 0,22-0,87). Conclusion: Exposure to addiction and medical services is associated with HCV treatment initiation. These results suggest that such services efficiently play their role as entry points for HCV treatment. Alternatively, IDU who have initiated HCV treatment, regardless of the viral response outcome, may have adopted a proactive stance towards improving their overall health. Incarceration on the other hand seems to be an obstacle to HCV treatment uptake.

No description available.